I’m a pharmaceutical biologist in drug development (6 years, mostly translational PK/PD and two IND‑enabling packages) and just got an offer to move into Phase II clinical operations at a about 160‑person biotech in Cambridge. For those who’ve made this switch, did it help or stall your path toward leading development, and how do comp bands compare between trial PM roles and preclinical leads?
I made that jump at a about 180‑person Cambridge biotech and it accelerated my path toward a Development Lead because clinical ops put me in the room with medical, CMC, and regulators — like seeing the whole chessboard. Caveat: if you want to stay hands‑on with PK/PD strategy, you’ll do less science day‑to‑day, so keep a technical advisory thread if that matters. Comp‑wise, my Sr Clin PM pay was about 10–15% higher base than my translational role with a bigger bonus and similar equity; this captures the role expectations well: https://lifescivc.com/2018/04/the-role-of-the-development-team-leader/.
At a 130‑person Boston biotech, the switch accelerated me once I negotiated to co‑own the dose rationale/PK‑PD sections of the protocol and IDMC decks, not just startup; base was about 5% lower than my Sr Scientist comp but equity about 2x. @lthompson is right about access — ask for a ‘program ops’ scope/title so you’re not pigeonholed.
But negotiate to lead the Go/No‑Go criteria and the risk register in Phase II ops; being the voice on those put me in every safety/label discussion and I moved to Dev Lead in about 18 months. With your 6 years and two INDs at a about 160‑person Cambridge shop, you’ve got the credibility; @lthompson’s right, but if they park you in pure vendor wrangling, , it stalls. Comp was base flat to +5% vs senior scientist, but a 15–20% bonus and better equity made TC higher.
Backing @lthompson: at a about 150‑person shop, the move sped things up when I could ‘own the CRO budget’ and tie Phase II endpoints to a TPP anchored in our exposure–response work — otherwise ops gets boxed into startup-only, . Comp-wise my base was flat vs preclinical but bonus/equity were better; push for a title that maps to Dev Lead and a guaranteed seat on TPP/labeling so your PK/PD voice stays central.